Julian P. Villacastin/LinkedIn
Sep 7, 2026, 18:31
Julian P. Villacastin: LAAC as a Treatment Option When Long-Term Anticoagulation Is Problematic
Julian P. Villacastin, Director of CardioRed1, Head of the Cardiology Department at Hospital Clínico San Carlos,shared a post on X about a recent article Elmir Omerovic and Björn Redfors co-authored, published in European Heart Journal, adding:
“CHAMPION-AF and CLOSURE-AF: reconciling contrasting results.
LAAC is a real treatment option for patients in whom long-term anticoagulation is genuinely problematic.”
Title: CHAMPION-AF and CLOSURE-AF: reconciling contrasting results
Authors: Elmir Omerovic, Björn Redfors
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 7, 2026, 18:29Geoff Stooke: How Hemophilia Led the Massie Family to the Romanovs and Ronald Reagan
-
Sep 7, 2026, 18:27Sam Mbunya: September is Sickle Cell Awareness Month
-
Sep 7, 2026, 18:25David Akande: Things I Wish People Knew About Sickle Cell
-
Sep 7, 2026, 18:24Prachi Bansal: A Small Act of Giving, A Lifelong Lesson in Humanity
-
Sep 7, 2026, 17:27Isaac Okello: From Global Dialogue to Local Impact in Sickle Cell Disease
-
Sep 7, 2026, 17:03Caitlin Raymond: The People With “Golden Blood”
-
Sep 7, 2026, 16:51Re-exposing Patients to Heparin After Heparin-Induced Thrombocytopenia – JTH
-
Sep 7, 2026, 16:39Sara Lojo Lendoiro: When Thrombosis in Pregnancy Requires More Than One Specialty
-
Sep 7, 2026, 16:29King Harald V’s Illness and the Broader Clinical Burden of Autoimmune Hemolytic Anemia